of 70 (when to stop is determined by age, PSA values, and health factors) would reduce prostate cancer mortality in Black men (~30% relative reduction) without significantly increasing the rate of overdiagnosis.Conclusions:Black men should obtain information about PSA screening for prostate cancer....
The National Comprehensive Cancer Network (NCCN, v.2.2018) recommends baseline screening beginning at age 45. "African-American men and men with a family history of prostate cancer represent high-risk groups. However, the panel believes that current data are insufficient to definitively inform the b...
Aging in men (beginning at age 50) is the greatest risk factor for both BPH and prostate cancer. In addition, having a father or brother with prostate cancer doubles the risk for prostate cancer; however, African American males have the highest risk for prostate cancer. Research suggests that...
Introducing the 2010 American Cancer SocietyProstate Cancer Screening GuidelineOtis W. Brawley, MD, Chief Medical Off i cer, Editor-in-Chief, CA: A Cancer Journal for Clinicians, American Cancer Society, Atlanta, GA;Ted Gansler, MD, MBA, Director of Medical Content, Editor, CA: A Cancer Jou...
New research confirms that the controversial decision by Warren Buffet – the 81-year-old CEO of Berkshire Hathaway – to undergo a blood test screening for prostate cancer despite his age is hardly unusual. Despite recommendations in 2008 from the United States Preventive Services Task Force agains...
In the ERSPC trial, the prostate cancer mortality rate ratio in the screening vs control group among men 70 years and older at randomization was 1.17 (95% CI, 0.82-1.66); however, a statistical test found no significant heterogeneity across age groups. In the PLCO trial, the analogous rate...
g: A decision guide Prostate cancer screening: A decision guideProstate cancer screening: A decision guideMyers, Ronald E
Prostate cancer screening based on prostate-specific antigen (PSA) testing has been a matter of controversy. Although screening for prostate cancer was effective in reducing mortality, it resulted in overdiagnosis, which translated into unnecessary treat
Clinical Practice Guideline for Prostate Cancer ScreeningTreatment, Prostate Cancer
Selection of treatment for a patient with prostate cancer is often based on age and life expectancy. However, life expectancy estimates are often calculated solely on the basis of chronological age, overlooking comorbid conditions and their severity, whi